PL349838A1 - Dopamine d1 receptor agonist compounds - Google Patents

Dopamine d1 receptor agonist compounds

Info

Publication number
PL349838A1
PL349838A1 PL00349838A PL34983800A PL349838A1 PL 349838 A1 PL349838 A1 PL 349838A1 PL 00349838 A PL00349838 A PL 00349838A PL 34983800 A PL34983800 A PL 34983800A PL 349838 A1 PL349838 A1 PL 349838A1
Authority
PL
Poland
Prior art keywords
dopamine
receptor agonist
agonist compounds
compounds
receptor
Prior art date
Application number
PL00349838A
Other languages
English (en)
Inventor
Gary Tilbrook
Original Assignee
Cenes Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Ltd filed Critical Cenes Ltd
Publication of PL349838A1 publication Critical patent/PL349838A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PL00349838A 1999-02-17 2000-02-17 Dopamine d1 receptor agonist compounds PL349838A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903671.7A GB9903671D0 (en) 1999-02-17 1999-02-17 Dopamine D-1 receptor agonist compounds

Publications (1)

Publication Number Publication Date
PL349838A1 true PL349838A1 (en) 2002-09-23

Family

ID=10847990

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00349838A PL349838A1 (en) 1999-02-17 2000-02-17 Dopamine d1 receptor agonist compounds

Country Status (17)

Country Link
EP (1) EP1157009A1 (de)
JP (1) JP2002537288A (de)
KR (1) KR20010108228A (de)
CN (1) CN1142916C (de)
AU (1) AU767332B2 (de)
BR (1) BR0008329A (de)
CA (1) CA2363695A1 (de)
CZ (1) CZ20012973A3 (de)
EA (1) EA004745B1 (de)
GB (1) GB9903671D0 (de)
HU (1) HUP0200057A3 (de)
IL (1) IL144810A0 (de)
MX (1) MXPA01008294A (de)
NO (1) NO20013978L (de)
PL (1) PL349838A1 (de)
WO (1) WO2000049000A1 (de)
ZA (1) ZA200106478B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130576D0 (en) * 2001-12-20 2002-02-06 Cenes Ltd Dopamine D1 receptor agonist pro-drug compounds & derivatives
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
AU2006278514A1 (en) * 2005-08-03 2007-02-15 Mia Levite Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells by dopamine D1R agonists
CN101684096A (zh) * 2008-09-23 2010-03-31 中国科学院上海药物研究所 一类新型苯并氮杂卓类化合物及其制备方法和用途
CN102276531A (zh) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 一种甲磺酸非诺多泮的制备方法
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561305A (en) * 1975-07-02 1980-02-20 Smithkline Corp Benzazepine derivatives and pharmeceutical compositions containing them
US4111957A (en) * 1977-02-02 1978-09-05 Smithkline Corporation Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4265889A (en) * 1978-05-05 1981-05-05 Smithkline Corporation 6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4707483A (en) * 1985-12-20 1987-11-17 Smithkline Beckman Corporation 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders
US4861771A (en) * 1989-01-27 1989-08-29 Smithkline Beckman Corporation Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as prodrugs

Also Published As

Publication number Publication date
AU2563200A (en) 2000-09-04
WO2000049000A1 (en) 2000-08-24
ZA200106478B (en) 2002-02-07
HUP0200057A2 (en) 2002-08-28
NO20013978D0 (no) 2001-08-15
CN1341102A (zh) 2002-03-20
NO20013978L (no) 2001-08-15
BR0008329A (pt) 2002-01-29
MXPA01008294A (es) 2002-07-02
AU767332B2 (en) 2003-11-06
EP1157009A1 (de) 2001-11-28
KR20010108228A (ko) 2001-12-07
CN1142916C (zh) 2004-03-24
CZ20012973A3 (cs) 2002-01-16
GB9903671D0 (en) 1999-04-14
IL144810A0 (en) 2002-06-30
EA004745B1 (ru) 2004-08-26
HUP0200057A3 (en) 2004-03-29
CA2363695A1 (en) 2000-08-24
EA200100783A1 (ru) 2002-02-28
JP2002537288A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
ATE449768T1 (de) Triazolverbindungen mit dopamin-d3- rezeptoraffinität
HK1091403A1 (en) 5-ht 1a receptor subtype agonist
EP1187614A4 (de) Substituierte piperidine als melanocortin-4 rezeptoragonisten
AU6497701A (en) Melanocortin receptor agonists
AU2001280568A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HUP0202142A2 (en) Macrophage scavenger receptor antagonists
AU4098501A (en) Estrogen agonist/antagonist metabolites
AU2001273508A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
IL146151A0 (en) Human-g-protein receptor
HUP0101746A3 (en) Phenylsulfonamide-phenylethylamines usefull as dopamine receptors
IL144810A0 (en) Dopamine d1 receptor agonist compounds
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
EP1520856A4 (de) Androgenrezeptorantagonist
AU6230698A (en) Dopamine d4 receptor antagonist
AU4511901A (en) Nonpeptide kappa opioid receptor antagonists
GB0130576D0 (en) Dopamine D1 receptor agonist pro-drug compounds & derivatives
AU4337599A (en) Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands
GB0020710D0 (en) Dopamine D1 receptor agonist pro-drug compounds & derivatives
SI1077935T1 (en) Phenylsulfonamide-phenylethylamines useful as dopamine receptors
AU2825100A (en) Heterocyclic compounds having affinities for serotonin receptors
AU3128700A (en) Combinations of dopamine receptor antagonists with dopamine agonists
HK1048803A1 (en) β 2-ADRENERGIC RECEPTOR AGONISTS
PL356171A1 (en) Beta2-adrenergic receptor agonists
GB0107914D0 (en) 7tm receptor hlwar77

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)